Avinger, Inc. (NASDAQ:AVGR) last session’s volume of 0.34 million shares was lower than its average volume of 1.97 million shares. The stock, after opening at $0.2479, hit $0.23 through the close by scoring -4.3%.Avinger, Inc. (AVGR) Analyst Opinion
Avinger, Inc. has a consensus outperform rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 7.01% of shares outstanding. The stock sank -28.69% last month and is down -93.74 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover AVGR having a buy-equivalent rating. Analysts have placed a $2 price target on Avinger, Inc., suggesting a 769.57% gain from recent close. It’s currently trading about -94.91% below its 52-week high.Avinger, Inc. Earnings Surprise
Avinger, Inc. (AVGR) revenue totaled $3 million down -14.04% from the previous quarter.
This stock (AVGR) is ahead of its 52-week low with 10.29%. Its last month’s stock price volatility remained 16.94% which for the week stands at 11.6%. The share price has moved backward from its 20 days moving average, trading at a distance of -10.83% and stays -23.07% away from its 50 days moving average. Over the last five days, shares have managed 1.53% gains and now is down -66.15% since hitting its 200-day moving average of $0.3582. Avinger, Inc. (AVGR) has made its way to a 12-month decline of -94.14%.
Turning to Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), its shares were trading at $3.33 a retreat of $-0.16, on the trading floor. The stock, after opening at $3.54, touched a high of $3.6 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.3. Arrowhead Pharmaceuticals, Inc. has 1 buy ratings, 2 holds and 0 sells even after the stock tumbled -26.65% from its high of $4.54 to a $246.92 million market value through last close.Arrowhead Pharmaceuticals, Inc. (ARWR) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.5 to 2.25 during a month. Analysts set a 12-month price target of $3.63 a share. The target implies a 9.01% spike from where the shares are currently trading. Also, the current price highlights a discount of 80.18% to analysts’ high consensus price target.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Intraday Trading
The counter witnessed a trading volume of 0.75 million shares versus an average volume of 1.08 million shares during last trading session. Its last month’s stock price volatility remained 8.96% which for the week approaches 6%. The lowest price the stock reached in the last trading day was $3.29 and compares with the $1.20 52-week low. The stock recovered 177.5% since its low point and has performed 114.84% year-to-date.